Duchenne muscular dystrophy: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)

  NCT06241950· Sarepta Therapeutics, Inc.· Updated 6 Nov 2026

  “Study is being terminated due to a business decision.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Phase 2 Trial to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tegacorat in Male Participants 4 to <7 Years of Age With Duchenne Muscular Dystrophy

  NCT07911995· Grünenthal GmbH· Source

• Duchenne Electronic Health Record Study

  NCT07609394· The Duchenne Registry· Source

• A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)

  NCT06128564· Hoffmann-La Roche· Source

• A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)

  NCT06450639· Hoffmann-La Roche· Source

• Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials

  NCT07674758· Vanderbilt University Medical Center· Source

• CureDuchenne Link®: A Resource for Research

  NCT04972604· CureDuchenne· Source

• Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

  NCT04281485· Pfizer· Source

• A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

  NCT06138639· Solid Biosciences Inc.· Source

• The Duchenne Registry

  NCT02069756· The Duchenne Registry· Source

• A Study to Evaluate the Safety and Tolerability of Rituxan in Duchenne Muscular Dystrophy

  NCT07475754· Peking Union Medical College Hospital· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 2
• Organoids 3
• CRISPR-Cas Systems 13
• Gene Expression Profiling 7
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 4
• Exome Sequencing 5
• Proteomics 13
• Metabolomics 1
• Mass Spectrometry 2
• Immunohistochemistry 3
• Magnetic Resonance Imaging 19
• Machine Learning 2
• Cohort Studies 8

See which targets of this disease your abstract mentions, and go to the people working on them.